欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

已收盘 07-16 16:08:34

6.220

+0.650

+11.67%

最高6.220	最低5.410	成交量273.15万
今开5.570	昨收5.570	日振幅14.54%
总市值50.69亿	流通市值50.69亿	总股本8.15亿
成交额1,643万	换手率0.34%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":6.22,"timestamp":1784189314003,"preClose":5.57,"halted":0,"volume":2731523,"delay":0,"changeRate":0.11669658886894065,"floatShares":815000000,"shares":815000000,"eps":-0.23146514891381892,"marketStatus":"已收盘","change":0.65,"latestTime":"07-16 16:08:34","open":5.57,"high":6.22,"low":5.41,"amount":16433491,"amplitude":0.145422,"askPrice":6.22,"askSize":10500,"bidPrice":6.08,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.23231346868458805,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784251800000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":5.57,"openAndCloseTimeList":[[1784165400000,1784174400000],[1784178000000,1784188800000]],"volumeRatio":2.448874,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477/wiki","defaultTab":"wiki","newsList":[{"id":"2651494623","title":"AI制药正迎来关键一跃 资本巨头竞逐新赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2651494623","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651494623?lang=zh_cn&edition=full","pubTime":"2026-07-16 07:38","pubTimestamp":1784158699,"startTime":"0","endTime":"0","summary":"据证券时报，7月初，明星人工智能（AI）企业Anthropic发布了面向科学家和制药企业的专属AI产品ClaudeScience，并宣布将启动自主药物研发项目，在AI制药领域投下一枚“重磅炸弹”。紧接着，国内AI制药企业英硅智能宣布，与日本制药巨头武田制药达成全球战略合作协议，交易总金额最高可达6亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607163808067814.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607163808067814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","QTOC","ARTY","CHAT","AGIX","AIPO","01477","VTHR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651491270","title":"港股概念追踪 | 合作密集落地+巨头扎堆进场 AI制药商业化驶入快车道(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2651491270","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651491270?lang=zh_cn&edition=full","pubTime":"2026-07-16 07:08","pubTimestamp":1784156921,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，AI制药商业化落地提速。英硅智能日前发布公告，旗下首款由自有生成式AI平台驱动的候选药物启动三期临床试验。过去几年，AI制药市场持续升温。英硅智能在2026年上半年迎来商业化合作的密集落地。6月10日，字节跳动AI制药业务启动拆分与独立融资的消息，在科技圈与医药圈均引发广泛关注。剂泰科技拥有中国首个完成III期临床的AI赋能制剂新药MTS-004。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468203.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03696","AIPO","BK1574","AGIX","BK4585","QTOC","BK1191","CHAT","07666","BK4588","VTHR","BK1161","ARTY","BK1141","01477","KCAI","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651692684","title":"汇宇制药（688553）披露2026年第一次临时股东会决议公告，7月15日股价上涨3.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651692684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651692684?lang=zh_cn&edition=full","pubTime":"2026-07-15 22:06","pubTimestamp":1784124385,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘，汇宇制药报收于13.16元，较前一交易日上涨3.3%，最新总市值为82.37亿元。该股当日开盘12.5元，最高13.6元，最低12.47元，成交额达4.37亿元，换手率为6.55%。近日，四川汇宇制药股份有限公司披露2026年第一次临时股东会决议公告。公告显示，公司于2026年7月15日召开2026年第一次临时股东会，会议由董事会召集，董事长丁兆主持，采用现场与网络投票结合方式召开，出席股东及代理人共153人，代表表决权总数199,267,528股，占公司表决权总数的31.9461%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500044576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1191","01477","BK0239","688553"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105452","title":"佳兆业健康(00876.HK)拟更名为“青海制药集团有限公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105452","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651105452?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:53","pubTimestamp":1784112827,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","00876","BK1222","BK1191","BK1239","BK1230","BK1121","BK1154","01477","02954"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451892","title":"歌礼制药-B(01672)选定同类首创口服小分子GIPR激动剂ASC48和口服小分子 GLP-1R激动剂ASC30的固定剂量复方制剂进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451892","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451892?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:52","pubTimestamp":1784109149,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，已选定有望成为同类首创 口服小分子的GIPR激动剂ASC48，和口服小分子GLP-1R激动剂ASC30的固定剂量复方制剂进行临床开发。连续八天每日一次口服ASC30_48 FDC，其减重效果较ASC30及ASC48单药分别相对提升52%和518%。预计将于2026年第四季度向美国食品药品监督管理局递交ASC30_48 FDC 口服片的新药临床试验申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","GIPR","JDOC","BK4144","01672","BK4590","BK1161","BK1574","BK4160","01477","GLP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651451818","title":"歌礼制药-B(01672.HK)选定同类首创口服小分子GIPR激动剂ASC48和口服小分子 GLP-1R激动剂ASC30的固定剂量复方制剂进行临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2651451818","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651451818?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:52","pubTimestamp":1784109149,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","01477","BK1161","01672","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455892","title":"东富龙：制药装备行业呈现分化修复格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651455892?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:36","pubTimestamp":1784104586,"startTime":"0","endTime":"0","summary":"证券之星消息，东富龙(300171)07月15日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘:公司所在的医药装备行业是否有回暖迹象。谢谢东富龙回复：您好，在生物医药行业相关政策的促进下，激活了医药企业全周期融资，有利于促进生物医药企业加大研发及产能建设的投入，从而推动对制药装备、仪器及耗材的采购和使用。目前，制药装备行业呈现分化修复格局，国内市场竞争虽仍处于较激烈阶段，公司也将发挥自身产品技术与服务特点，利用差异化竞争优势把握市场机会。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","300171","BK0251","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651245363","title":"7月15日泽璟制药跌9.95%，汇添富创新医药混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651245363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651245363?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:21","pubTimestamp":1784103692,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日泽璟制药跌9.95%，收盘报132.73元，换手率5.66%，成交量14.98万手，成交额22.29亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共86家，其中持有数量最多的公募基金为汇添富基金的汇添富创新医药混合A。汇添富创新医药混合A目前规模为74.25亿元，最新净值1.7646，较上一交易日上涨0.15%，近一年下跌0.6%。汇添富创新医药混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500030682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1515","BK1191","01477","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810439","title":"港股早盘高开高走 恒指半日涨1.46% 创新药、猪肉概念强势","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810439","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651810439?lang=zh_cn&edition=full","pubTime":"2026-07-15 12:11","pubTimestamp":1784088667,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股早盘高开高走，三大股指均升逾1%。截至午间收盘，恒生指数上涨1.46%；国企指数涨1.16%；恒生科技指数涨1.39%。猪价底部大概率已现，预计周期临近上行。预计2026年半年度归属于上市公司股东的扣除非经常性损益的净利润约为人民币20.00亿元到人民币26.00亿元，与上年同期相比，将增加人民币18.62亿元到人民币24.62亿元，同比增长1349%到1784%。MiniMax盘中反复拉升，午间收涨14.96%。港股将受益于中国内地强劲而有韧性的经济表现，建议超配H股。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985921","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828714.EUR","BK1574","IE0032431581.USD","BK1576","02628","BK1549","BK1584","LU0819121731.USD","IE00BZ08YR35.GBP","SG9999002562.SGD","SG9999012710.SGD","LU0572944931.SGD","SGXZ62798434.SGD","02268","LU0348784397.USD","IE0008368742.USD","IE00BZ08YS42.EUR","LU0244354667.USD","LU0972618739.USD","HK0000165453.HKD","LU0348735423.USD","MCHmain","600028","LU0293314216.USD","LU0871576103.HKD","LU1048596156.SGD","LU1794554557.SGD","LU2097828474.EUR","LU0708995583.HKD","LU0043850808.USD","LU0588546209.SGD","LU2125910500.SGD","LU0588545904.SGD","LU0516423091.SGD","LU0405327494.USD","07500","LU1226288170.HKD","LU1303224171.USD","SG9999002463.SGD","BK1583","BK1603","LU0051755006.USD","LU0502904849.HKD","LU0823426308.USD","LU0516422366.SGD","LU1251922891.USD","SG9999001226.SGD","LU0634319403.HKD","LU0455707207.USD","LU0456827905.SGD","06869","01093","LU0348767384.USD","SG9999006597.SGD","LU0315179316.USD","LU0516423174.USD","LU1188198961.HKD","SG9999014674.SGD","03037","LU1785774172.SGD","LU0039217434.USD","LU0169518387.USD","LU0856984785.SGD","LU0348783233.USD","LU0588545490.SGD","LU0181495838.USD","LU0821914370.USD","LU0611395673.USD","LU0862451753.SGD","IE00BZ08YT58.USD","00981","LU0307460666.USD","LU2242644610.SGD","00100","02359","513600","LU0348766576.USD","LU0173614495.USD","SCHYY","LU0163747925.USD","LU0516422440.USD","LU0979878070.USD","LU0588545730.USD","01610","688981","LU0287142896.SGD","01177","LU1961090484.USD","BK1191","LU0072913022.USD","BK1550","LU2399975544.HKD","02419","BK1226","LU0405327148.USD","00857","BK1161","00386","LU1046422090.SGD","LU1152091168.USD","LU0675040207.SGD","BK1163","LU0516422952.EUR","LU0865486749.SGD","LU1224444064.USD","LU0315178854.USD","LU0531971595.HKD","09926","LU2778985437.USD","01928","BK1184","603259","SBHMY","07300","LU0348825331.USD","LU2476274308.USD","LU0463099449.HKD","BK1526","HK0000286598.CNH","LU0359202008.SGD","IE00B5MMRT66.SGD","SG9999012744.USD","01801","SG9999001093.SGD","LU1969619763.USD","LU1226287792.SGD","BK1614","LU0890818403.SGD","LU1807302812.USD","LU0072462343.USD","LU0251144936.SGD","IE00B0JY6N72.USD","LU1675838814.USD","LU0140636845.USD","IE00B19Z5X02.USD","BK1149","LU0651947912.USD","BK1528","LU2293587155.HKD","LU1880383366.USD","LU1515016050.SGD","LU0640798160.USD","BK1562","BK1607","LU0326950275.SGD","LU2097828631.EUR","LU2328871848.SGD","LU1719994722.HKD","LU0320764599.SGD","LU0501845795.SGD","LU1497734951.SGD","LU1008478684.HKD","601857","LU1808992512.USD","IE00B031HY20.USD","KURE","LU1813983027.USD","LU1993786604.SGD","LU0067412154.USD","LU1242518931.SGD","LU2045819591.USD","LU3063872942.SGD","IE0008369823.USD","LU1152091754.HKD","SG9999003461.SGD","LU1023057109.AUD","LU2476274720.SGD","02269","IE00BPRC5H50.USD","LU0823426480.USD","IE00BQJZWZ67.USD","LU0327786744.USD","LU1282651048.USD","LU2488822045.USD","LU0348805143.USD","BK1589","LU1960683339.HKD","LU1051768304.USD","601628","LU1226287529.USD","LU0417516738.SGD","LU1497733557.USD","LU0417516571.SGD","01477","SG9999012736.USD","HSTECH","SGXZ86797644.SGD","LU0540923850.HKD","HHImain","002714","LU1242518857.USD","LU0314109678.HKD","LU0196878994.USD","BK1141","09115","LU1688375341.USD","HSI","BK1521","02714","IE00B543WZ88.USD","03115","LU0211977185.USD","LU1115378108.SGD","LU1634259557.SGD","WXXWY","LU0880133367.SGD","LU1226287875.USD","LU1951186391.HKD","LU1211504680.USD","LU1770034418.SGD","BK1117","BK1237","LU1720050803.USD","LU0862451837.USD","LU0348783662.USD","LU2097828805.USD","LU0359201885.HKD","LU1051769294.HKD","LU0052750758.USD","LU2257852520.SGD","LU0417516902.SGD","06990","03419","LU1048588211.SGD","LU0561508036.HKD","LU0228367735.SGD","LU0164865239.USD","LU0651946864.USD","LU0441854154.USD","07200","LU0469268626.HKD","LU1634259391.SGD","BK1610","LU0828237940.HKD","LU1497733631.SGD","BK1172","LU0359201612.USD","02833","83115","IE00BWDBJ730.SGD","LU1522347837.USD","02800","LU1226288253.USD","SG9999004220.SGD","LU0348827113.USD","601869","LU0456846285.SGD","BK1523","SG9999012728.SGD","LU1282651121.HKD","BK1506","LU1328277881.USD","LU1831875114.USD","82800","BK1515","LU2039709279.SGD","LU2097828557.USD","LU0048597586.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"other","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","LU0502904849.HKD","LU1961090484.USD","BK1141","BK1574","01530","LU0348825331.USD","LU0348767384.USD","06978","01801","MEDX","SG9999014674.SGD","06990","LU1720050803.USD","LU0455707207.USD","LU2097828714.EUR","LU2097828631.EUR","BK1593","BK1589","LU2097828805.USD","BK1191","KURE","LU2778985437.USD","LU2476274308.USD","LU0417516571.SGD","06855","LU2097828474.EUR","LU0561508036.HKD","LU2488822045.USD","09926","02157","IE00BPRC5H50.USD","LU0348827113.USD","LU2399975544.HKD","02268","LU2097828557.USD","09995","LU0348784397.USD","159992","02162","01477","IE00B543WZ88.USD","LU0540923850.HKD","BK1587","LU2328871848.SGD","LU0417516738.SGD","BK1161","LU0417516902.SGD","LU0634319403.HKD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651179148","title":"歌礼制药-B(01672)7月14日斥资209万港元回购20万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651179148","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651179148?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:33","pubTimestamp":1784021634,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年7月14日，该公司斥资209万港元回购20万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1161","01672","BK1574","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651712703","title":"大摩：调整中生制药(01177)2026至28年每股盈测 重申“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2651712703","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651712703?lang=zh_cn&edition=full","pubTime":"2026-07-14 14:47","pubTimestamp":1784011658,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，大致维持对中生制药(01177)创新药的预测，但鉴于最新的销售政策及即将进行的带量采购，下调其仿制药及生物类似药的销售预测。同时，该行上调其商业授权的收入预测，以反映Sanofi及GSK的首付款将于今年入账，以及未来潜在的里程碑付款与新商业授权收入。目标价维持7.8港元，重申“增持”，悲观情境目标价则由4.8港元降至4.5港元。该行将中生制药于2026至28年各年剔除商业授权收入后的每股盈测下调2%至3%，以主要反映仿制药销售预测下降。不过，计及商业授权收入后，该行对公司2026至28年各年每股基本盈测则分别上调13.6%、5.5%及3.9%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651456171","title":"股市必读：汇宇制药（688553）7月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651456171","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651456171?lang=zh_cn&edition=full","pubTime":"2026-07-14 01:04","pubTimestamp":1783962254,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘，汇宇制药报收于12.23元，下跌3.17%，换手率3.03%，成交量15.38万手，成交额1.91亿元。公司严格遵守税法规定，依法纳税，税务处理均经专业机构审计确认，不存在税务违规情形。投资者： 近期公司持股6%的股东及公司持股4%的股东相继减持公司股份，相关减持计划都提到他们都没有一致行动人。当日关注点交易信息汇总：7月13日主力资金净流入1505.26万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400000957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0239","BK1191","688553","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651113913","title":"汇宇制药：前述两名股东不构成一致行动人","url":"https://stock-news.laohu8.com/highlight/detail?id=2651113913","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651113913?lang=zh_cn&edition=full","pubTime":"2026-07-13 18:24","pubTimestamp":1783938261,"startTime":"0","endTime":"0","summary":"投资者提问：近期公司持股6%的股东及公司持股4%的股东相继减持公司股份，相关减持计划都提到他们都没有一致行动人。根据《上市公司收购管理办法》第八十三条之规定，前述两名股东虽存在亲属关系，但不属于该条款规定的“近亲属”范畴，且双方不存在通过协议、合作、关联等其他安排共同扩大上市公司股份表决权的情形，因此不构成一致行动人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300029200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651905461","title":"明宇制药港股IPO：补充资金、化解28亿金融负债的“一场战役”","url":"https://stock-news.laohu8.com/highlight/detail?id=2651905461","media":"尺度商业","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651905461?lang=zh_cn&edition=full","pubTime":"2026-07-13 17:25","pubTimestamp":1783934708,"startTime":"0","endTime":"0","summary":"…","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"netease_stock","url":"https://www.163.com/dy/article/L1O0KFCJ0519B826.html","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.163.com/dy/article/L1O0KFCJ0519B826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"netease_stock","symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651019168","title":"2025年度中国医药工业营收百强榜发布，齐鲁制药连续三年位列第三","url":"https://stock-news.laohu8.com/highlight/detail?id=2651019168","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651019168?lang=zh_cn&edition=full","pubTime":"2026-07-13 15:42","pubTimestamp":1783928549,"startTime":"0","endTime":"0","summary":"7月11日至12日，由中国医药工业信息中心等单位主办的第43届全国医药工业信息年会 & 2026北京·昌平生命科学论坛在北京召开。大会发布了备受行业关注的“2025年度中国医药工业主营业务收入前100位企业”以及“2026年中国医药研发产品线示范工业企业”“2026年中国医药工业企业社会责任优秀案例”等系列榜单。齐鲁制药集团第十一次跻身中国医药工业主营业务收入前100位企业，连续三年位居第三位。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1783928491744277655","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["01477","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650502881","title":"华平投资拟斥资逾70亿美元收购美特种制药企业 携手阿联酋主权基金深化医疗产业布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2650502881","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650502881?lang=zh_cn&edition=full","pubTime":"2026-07-12 14:43","pubTimestamp":1783838580,"startTime":"0","endTime":"0","summary":"据知情人士日前披露，全球顶尖私募股权投资机构华平投资正与美国特种制药及罕见病药品服务商Pantherx Rare展开深度谈判，拟以超过70亿美元（含债务）的交易对价将其收归麾下。此举标志着在全球私募股权资本面临投资组合退出滞压的背景下，医疗健康核心资产再度成为国际大型财团竞逐的焦点。　　知情人士指出，华平投资此次计划携手战略合作伙伴——阿联酋主权财富基金阿布扎比投资局共同出资。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-12/doc-inihppwh9790505.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","159891","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650158302","title":"明宇制药冲刺港股：5个月无收入 亏2.1亿 估值39亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2650158302","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650158302?lang=zh_cn&edition=full","pubTime":"2026-07-11 07:05","pubTimestamp":1783724739,"startTime":"0","endTime":"0","summary":"明宇制药有限公司（简称：“明宇制药”）日前更新招股书，准备在港交所上市。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260711/6391935014057700188547397.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260711/6391935014057700188547397.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n34365/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["KCAI","BK4588","BK1574","BK4585","BK1191","01477","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907869","title":"港股异动 | 中生制药(01177.HK)盘中涨近7% TQC3721海外权益以总额最高19亿美元授权给阿斯利康","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907869","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650907869?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:33","pubTimestamp":1783665234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1589","IE00BZ08YS42.EUR","BK1515","HK0000165453.HKD","IE00BZ08YT58.USD","01477","BK1574","IE00BZ08YR35.GBP","01177","BK1191","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650906735","title":"铂科新材、明宇制药递表港交所主板；紫金矿业预计半年度归母净利润同比增加约169%丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2650906735","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650906735?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:11","pubTimestamp":1783653093,"startTime":"0","endTime":"0","summary":"铂科新材、明宇制药递表港交所主板；紫金矿业预计半年度归母净利润同比增加约169%丨港交所早参","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607103801482278.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801482278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["601899","IPOS","02259","01477","300811","02899"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.1391},{"period":"1month","weight":0.067},{"period":"3month","weight":-0.3174},{"period":"6month","weight":-0.2553},{"period":"1year","weight":-0.4124},{"period":"ytd","weight":-0.2473}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.0065},{"period":"3month","weight":-0.0649},{"period":"6month","weight":-0.0806},{"period":"1year","weight":0.0037},{"period":"ytd","weight":-0.037}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.087204},{"month":6,"riseRate":0.666667,"avgChangeRate":0.062947},{"month":7,"riseRate":0.5,"avgChangeRate":0.015174},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}